Tags: Drug.
ACAM2000 is a smallpox vaccine developed by Acambis. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on 31 August 2007. It contains live vaccinia virus cloned from the same strain used in an earlier vaccine Dryvax. While the Dryvax virus was cultured in the skin of calves and freeze-dried ACAM2000s virus is cultured in kidney epithelial cells (Vero cells) from an African green monkey. Efficacy and adverse reaction incidence are similar to Dryvax.